Progress in Treatment of Non-Small Cell Lung Cancer Harboring HER2 Aberrations

Figures & data

Table 1 Results of Clinical Data Targeting HER2 Aberrations Among Lung Cancer Patients Reported in Various Trials

Drug	Author(Year)	Trial	HER2 Aberrations	No. Patients	ORR (%)	mPFS (m)	mOS (m)	DoR (m)	Sensitive HER2 Subtype
Afatinib	De Greve et al (2015)^Citation36	Retrospective	HER mutation	7	0	4.25	NA	4	NA
	Ou et al (2017)^Citation27	Retrospective	HER2 mutation	15	27(4/15)	NA	NA	NA	NA
	Liu Z et al (2016)^Citation31	Retrospective	HER2 ex20ins	19	15.8(3/19)	4.5	11.5	NA	HER2^G778_P780dup
	Peters S et al (2018)^Citation35	Retrospective	HER2 ex20ins	28	19 (3/16)	NA	NA	9.6	HER2^YVMA
	Dziadziuszko R et al (2019)^Citation33	Phase II trial	HER2 ex20ins	13	7.7(1/13)	3.7	13.1	NA	HER2^YVMA
	Fang W et al (2019)^Citation25	Retrospective	HER2 ex20ins	32	15.6(5/32)	3.2	NA	NA	HER2^G778_P780dup, HER2^G776delinsVC
	Lai et al (2018)^Citation34	Retrospective	HER2 ex20ins, HER2^V659E (ex17) HER2^S310F (ex8)	27	13(3/23)	NA	7	3	HER2ex20ins
Neratinib	Hyman DM et al (2018)^Citation39	Phase II trial	HER2 ex20ins HER2^S310F(ex8) HER2^L755S(ex19)	26	3.8(1/26)	5.5	NA	NA	HER2ex20ins
Pozitinib	Robichaux et al (2018)^Citation42	Phase I/II trial	HER2 ex20ins	12	42(5/12)	5.6	NA	4.6	HER2^YVMA HER2^G778_P780dup
Dacomtinib	Kris et al(2015)^Citation44	Phase II trial	HER2 ex20ins	26	12(3/26)	4	9	NA	HER2^G778_P780dup
			HER2 amplification	4	0	1,1,5,5	5,7,15,22	NA	NA
Pyrotinib	Wang Y et al (2019)^Citation45	Phase II trial	HER2 ex20ins	15	53.3	6.4	12.9	7.2	HER2ex20ins
	Zhou C et al (2020)^Citation46	Phase II trial	HER2 ex20ins	60	31.7(19/60)	NA	NA	1.0	HER2ex20ins
TAK-778(Mobocertinib)	Gonzalvez F et al(2020) (AACR 2020)		EGFR ex20ins HER2 ex20ins	60	34.78(21/60)	NA	NA	NA	NA
Trastuzumab +Pertuzumab	Hainsworth et al (2018)^Citation50	Phase IIa trial	HER2 mutation	14	21(3/14)	NA	NA	NA	NA
			HER2 overexpress or amplification	16	13(2/16)	NA	NA	NA	NA
T-DM1	Peters S et al (2019)^Citation82	Phase II trial	HER overexpression 2+	29	0	2.6	12.2	NA	NA
			HER overexpression 3+	20	20%	2.7	12.1	NA	NA
	Li BT et al (2018)^Citation52	Phase II trial	HER2 mutations	18	44(8/18)	5	NA	4	NA
DS8201	Tsurutani J et al(2020)^Citation55	Phase I trial	HER2 mutations	11	88.2	14.1	NA	NA	NA
			HER2 overexpression (2+ or 3+)	18	58.5	14.1	NA	NA	NA
	Smit EF et al (2020)^Citation56	Phase II trial	HER2 mutations	42	61.9	14	NA	NA	NA

Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018;554(7691):189–194. doi:10.1038/nature25475

 PubMed Web of Science ®Google Scholar

Ou SI, Schrock AB, Bocharov EV, et al. HER2 Transmembrane Domain (TMD) mutations (V659/G660) that stabilize homo- and heterodimerization are rare oncogenic drivers in lung adenocarcinoma that respond to afatinib. J Thorac Oncol. 2017;12(3):446–457. doi:10.1016/j.jtho.2016.11.2224

 PubMed Web of Science ®Google Scholar

Liu Z, Wu L, Cao J, et al. Clinical characterization of ERBB2 exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patients. Onco Targets Ther. 2018;11:7323–7331. doi:10.2147/OTT.S173391

 PubMed Web of Science ®Google Scholar

Hainsworth JD, Meric-Bernstam F, Swanton C, et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa Multiple Basket Study. J Clin Oncol. 2018;36(6):536–542. doi:10.1200/JCO.2017.75.3780

 PubMed Web of Science ®Google Scholar

De Greve J, Moran T, Graas M-P, et al. Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. Lung Cancer. 2015;88(1):63–69. doi:10.1016/j.lungcan.2015.01.013

 PubMed Web of Science ®Google Scholar

Fang W, Zhao S, Liang Y, et al. Mutation variants and co-mutations as genomic modifiers of response to afatinib in HER2-mutant lung adenocarcinoma. Oncologist. 2020;25(3):e545.

 PubMed Web of Science ®Google Scholar

Dziadziuszko R, Smit EF, Dafni U, et al. Afatinib in NSCLC with HER2 mutations: results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP). J Thorac Oncol. 2019;14(6):1086–1094. doi:10.1016/j.jtho.2019.02.017

 PubMed Web of Science ®Google Scholar

Li BT, Shen R, Buonocore D, et al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. J Clin Oncol. 2018;36(24):2532–2537. doi:10.1200/JCO.2018.77.9777

 PubMed Web of Science ®Google Scholar

Robichaux JP, Elamin YY, Tan Z, et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med. 2018;24(5):638–646. doi:10.1038/s41591-018-0007-9

 PubMed Web of Science ®Google Scholar

Tsurutani J, Iwata H, Krop I, et al. Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, Phase I Study in multiple advanced solid tumors. Cancer Discov. 2020;10(5):688–701. doi:10.1158/2159-8290.CD-19-1014

 PubMed Web of Science ®Google Scholar

Wang Y, Jiang T, Qin Z, et al. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib. Ann Oncol. 2019;30(3):447–455. doi:10.1093/annonc/mdy542

 PubMed Web of Science ®Google Scholar

Zhou C, Li X, Wang Q, et al. Pyrotinib in HER2-mutant advanced lung adenocarcinoma after platinum-based chemotherapy: a multicenter, open-label, single-arm, Phase II Study. J Clin Oncol. 2020;38(24):2753–2761. doi:10.1200/JCO.20.00297

 PubMed Web of Science ®Google Scholar

Liu S, Li S, Hai J, et al. Targeting HER2 aberrations in non-small cell lung cancer with osimertinib. Clin Cancer Res. 2018;24(11):2594–2604. doi:10.1158/1078-0432.CCR-17-1875

 PubMed Web of Science ®Google Scholar

Johnson BE, Janne PA. Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer. Clin Cancer Res. 2006;12(14 Pt 2):4436s–4440s. doi:10.1158/1078-0432.CCR-06-0629

 PubMed Web of Science ®Google Scholar

Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597–609. doi:10.1056/NEJMoa1914609

 PubMed Web of Science ®Google Scholar

Hotta K, Aoe K, Kozuki T, et al. A Phase II Study of trastuzumab emtansine in HER2-positive non-small cell lung cancer. J Thorac Oncol. 2018;13(2):273–279. doi:10.1016/j.jtho.2017.10.032

 PubMed Web of Science ®Google Scholar

Ettinger DS, Wood DE, Aisner DL, et al. NCCN guidelines insights: non-small cell lung cancer, version 2.2021. J Natl Compr Canc Netw. 2021;19(3):254–266. doi:10.6004/jnccn.2021.0013

 PubMed Web of Science ®Google Scholar